About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Expanded Access to RXDX-105 for Cancers With RET Alterations

NCT03052569·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Hoffmann-La Roche

Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosis of advanced cancer with RET alterations
Unable to participate in an ongoing RXDX-105 clinical trial
Willing and able to provide written, signed informed consent
Medically suitable for treatment with RXDX-105

You may not be if

Prior treatment with a TKI that has activity against RET alterations
Currently enrolled in an ongoing clinical study with any other investigational agent

The record

StatusNo longer available

PhaseNo phase

Taking part—

Started—

UpdatedApr 26, 2019

Conditions

Cancers With RET Alterations

Where1

Www.Ignyta.Com
San Diego, California, United States

Clareo Health | Expanded Access to RXDX-105 for Cancers With RET Alterations